Ricolinostat is Not a Highly Selective HDAC6 Inhibitor
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Phase separation rewires chromatin in breast cancer.
Benedetti R, Altucci L Nat Cancer. 2024; 5(11):1602-1604.
PMID: 39455848 DOI: 10.1038/s43018-024-00843-9.
Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor.
Bhattacharjee D, Bakar J, Chitnis S, Sausville E, Ashtekar K, Mendelson B Cell Chem Biol. 2023; 30(10):1211-1222.e5.
PMID: 37827156 PMC: 10715717. DOI: 10.1016/j.chembiol.2023.09.013.
References
1.
Lin A, Giuliano C, Palladino A, John K, Abramowicz C, Yuan M
. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med. 2019; 11(509).
PMC: 7717492.
DOI: 10.1126/scitranslmed.aaw8412.
View
2.
Winkler R, Magdefrau A, Piskor E, Kleemann M, Beyer M, Linke K
. Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition. Oncogene. 2022; 41(40):4560-4572.
PMC: 9525236.
DOI: 10.1038/s41388-022-02450-3.
View
3.
Lechner S, Malgapo M, Gratz C, Steimbach R, Baron A, Ruther P
. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol. 2022; 18(8):812-820.
PMC: 9339481.
DOI: 10.1038/s41589-022-01015-5.
View
4.
Heinzlmeir S, Lohse J, Treiber T, Kudlinzki D, Linhard V, Gande S
. Chemoproteomics-Aided Medicinal Chemistry for the Discovery of EPHA2 Inhibitors. ChemMedChem. 2017; 12(12):999-1011.
DOI: 10.1002/cmdc.201700217.
View
5.
Meyers R, Bryan J, McFarland J, Weir B, Sizemore A, Xu H
. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017; 49(12):1779-1784.
PMC: 5709193.
DOI: 10.1038/ng.3984.
View